<DOC>
	<DOC>NCT01543737</DOC>
	<brief_summary>The purpose of this study is to assess whether a single injection hyaluronic acid (HA) product is not inferior to a 3 injection HA product at 24 weeks (6 months), in terms of effectiveness in reducing pain when walking in patients suffering from symptomatic tibiofemoral osteoarthritis of the knee.</brief_summary>
	<brief_title>Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee</brief_title>
	<detailed_description>non-inferiority study of two HA products commercially availalble</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Age ≥ 40 and &lt; 85 Tibiofemoral osteoarthritis of the knee according to the American College of Rheumatology clinical criteria, in the KellgrenLawrence (KL) stages IIIII, confirmed by radiology (&lt; 3 months) Unilateral symptomatic osteoarthritis of the knee causing pain when walking (WOMAC A1 scale), assessed over the previous 24 hours on a scale of 0 to 10: Pain when walking: ≤ 3 and &lt; 8 Bilateral osteoarthritis of the knee, if pain in the other knee is &lt; 3 (10point numerical scale) Patient: outpatient, capable of walking 50 metres without a walking stick, crutches or a walker, capable of reading, understanding, signing and dating the patient information sheet Patient with social security cover Osteoarthritis of the knee in KellgrenLawrence (KL) stages I and IV Bilateral symptomatic osteoarthritis of the knee causing pain when walking (WOMAC A1 scale), assessed on a scale of 0 to 10: Pain when walking &gt; 3, in both knees Predominant symptomatic patellofemoral osteoarthritis of the knee Congestive manifestation of osteoarthritis of the knee defined according to the Knee Osteoarthritis FlareUps Score (KOFUS) criteria Last viscosupplementation of the affected knee &lt; 6 months before, last injection of corticosteroids &lt; 2 months before Known hypersensitivity to avian proteins and hyaluronic acids; History of joint replacement or major surgery in the affected knee in the last six months History of arthroscopy or surgery in the affected knee in the last three months Symptomatic hip disease on the same side or other side of the body Joint replacement or any other surgery planned in the next six months History of septic arthritis of the affected knee Skin complaint affecting the knee at the injection site Haemorrhagic disease contraindicating, in the doctor's opinion, any intraarticular injection In order to respect the pragmatic nature of the study: Any medical and / or pathological condition that, in the investigator's opinion, makes the subject unsuitable for inclusion Any medical and / or pathological condition that, in the investigator's opinion, would be a contraindication for an intraarticular injection Any other complaint that, in the investigator's opinion, would impede the assessment of the effectiveness of the affected knee Any treatment administered to the patient that may interfere with the interpretation of the study results Use of glucocorticosteroids (except inhaled corticosteroids) during the previous month Treatment with diacerein, avocado and soya unsaponifiables, glucosamine sulphate or chondroitin sulphate, started in the previous 3 months, or irregular doses over the previous 3 months Hard of hearing (not being able to follow a telephone conversation properly) Patient without a telephone Pregnant women or nursing mothers Participation in other clinical studies, within 30 days before inclusion</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>